SecBot SecBot

OMER

OMEROS CORP
Nasdaq· Pharmaceutical Preparations· Inc. WA· CIK 0001285819 Biotech & Drug Discovery
$16.68 −0.81 (−4.63%)
Nov 16 4:00 PM ET · prev $17.49
Market cap
$1.3B
Small cap
Consensus
Buy
80% Buy or better · 10 analysts
Median target
$27.50
+65% · range $22.00–33.00
1 year
+83.7%
from $9.08 · Nov 17
30 days
+2.0%
from $16.35
52-week range
$8.22–21.05
−21% from high · low Nov 19
Avg volume 20D
982.7K
Oct 29 spike 3.63M
Short interest
12.83M
≈17.7% of shares · +12.3%
Days to cover
9.6
at average volume
Insider net
−$2.3M
0 buyers · 4 sellers · 12 mo
New fund stakes
2
Q3 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read MIXED 6 reports · 90 days
Balance 0 bearish · 0 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 4/6

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $2.3M.

  • InstitutionsBULLISH

    Q3 2026: 23 added (2 new), 11 trimmed or exited. Largest new: Hrt Financial $10.1M.

  • AnalystsBULLISH

    8 of 10 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +12.3% to 12.83M shares. 9.6 days to cover, ≈17.7% of shares.

  • TrendDOWNTREND

    8% below its 50-day average.

Who's buying

13F· Q3 2026
2
new positions
0
exits
$10.1M
in new stakes · top 1 shown
FundMoveSharesValue
FEDERATED HERMES, INC.DOUBLED1,034,926$19.7M
MORGAN STANLEYDOUBLED804,002$15.3M
HRT FINANCIAL LPNEW529,260$10.1M
Squarepoint Ops LLCDOUBLED280,134$5.3M
Invesco Ltd.TRIM214,124$4.1M
BARCLAYS PLCDOUBLED99,346$1.9M
JPMORGAN CHASE & COADD55,667$1.1M
Quantinno Capital Management LPTRIM45,842$872.8K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 80% rate it Buy or better
Strong Buy3Buy5Hold2Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +65%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 14, 2026Cantor Fitzgerald
REITERATE
REITERATEOverweight
Sep 22, 2026Cantor Fitzgerald
UPGRADE
UPGRADEOverweight
Jun 26, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jun 10, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Washington

Corporate Lobbying

31 lobbying filings and 1 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$2.3M
sold · 4 insiders
DateInsiderTypeValue
Oct 28, 2026
Demopulos Gregory A MD
Chairman, CEO & President
Oct 28, 2026
AWARD500,000 sh
Sep 23, 2026
Borges David J.
VP, Finance & CAO
Sep 23, 2026
EXERCISE$155.8K
Sep 23, 2026
Borges David J.
VP, Finance & CAO
Sep 23, 2026
SELL$209.5K
Sep 22, 2026
Borges David J.
VP, Finance & CAO
Sep 22, 2026
SELL$209.5K
Sep 22, 2026
Borges David J.
VP, Finance & CAO
Sep 22, 2026
EXERCISE$19.6K
Sep 22, 2026
Borges David J.
VP, Finance & CAO
Sep 22, 2026
EXERCISE$14.7K
Aug 31, 2026
Cancelmo Peter B
VP, General Counsel
Aug 31, 2026
SELL$463.5K
Aug 31, 2026
Cancelmo Peter B
VP, General Counsel
Aug 31, 2026
EXERCISE$73.5K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
12,833,757
shares short
+12.3%
vs prior settlement
9.6
days to cover
≈17.7%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 Earnings result
OMER Q3 2026 Earnings: EPS $0.06 (+96.1% vs est)
Nov 6, 2026 SEC
Three institutional investors doubled or added to OMER positions in Q3 2026, with aggregate buying of $2.2M, while one…
INST-CLUSTER · Impact 3/10
Oct 30, 2026 SEC
Omeros granted CEO Gregory Demopulos a performance-based option to purchase 500,000 shares at $17.88 per share…
8-K · Impact 3/10
Oct 28, 2026 Insider
Demopulos Gregory A MD was granted 500,000 shares
Chairman, CEO & President
Sep 30, 2026 Inst.
FEDERATED HERMES, INC. · DOUBLED
1,034,926 shares ($19.7M)
Sep 30, 2026 Inst.
MORGAN STANLEY · DOUBLED
804,002 shares ($15.3M)
Sep 23, 2026 Insider
Borges David J. acquired via exercise 10,000 shares
VP, Finance & CAO @ $15.58 ($155.8K)
Sep 23, 2026 Insider
Borges David J. sold 10,000 shares
VP, Finance & CAO @ $20.95 ($209.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 16, 2026
Earnings result
OMER Q3 2026 Earnings: EPS $0.06 (+96.1% vs est)
Nov 12, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the…
Nov 11, 2026
Earnings date
OMER Q3 2026 Earnings Scheduled · 2026-11-11
Nov 5, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation ("Omeros" or the…
Nov 2, 2026
Clinical Trial
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
Phase 2 · TERMINATED

SecBot reports

12 filings · 3 bullish · 0 bearish · 1 mixed · 8 neutral
All OMER filing & press-release reports (12)